Research Library › Compound research
IGF-1 LR3 research examines a modified insulin-like growth factor-I analog. Its sequence and interactions with IGF-binding proteins make it a distinct experimental material, so findings should be interpreted within the tested model rather than treated as universal properties.
What does LR3 identify?
Long [Arg3] IGF-I, commonly written IGF-1 LR3, combines a 13-residue N-terminal extension with an arginine substitution at position 3 of the IGF-I sequence [1]. It should be distinguished from native IGF-I, des(1–3) IGF-I, and other analogs.
These names identify different materials. Do not substitute one for another when comparing a paper, a product listing, and a lot-specific certificate. The LR3 name also does not establish a particular batch’s production method, analytical characteristics, or biological activity.
Why do binding proteins matter?
Francis and colleagues compared recombinant IGF-I analogs in 1992 and investigated the importance of receptor binding and IGF-binding-protein interactions [1]. Long [Arg3] IGF-I behaved differently across their cell systems: responses in L6 rat myoblast assays differed from those in chicken embryo fibroblasts, where the analog was less potent than IGF-I.
The practical lesson is model dependence. A result in one assay does not justify describing LR3 as uniformly “stronger” than native IGF-I. The binding-protein environment, receptor context, and measured endpoint belong in the interpretation.
What is being measured?
Keep receptor-related observations, binding-protein interactions, cell proliferation, and protein-synthesis endpoints separate. A study may examine several of these, but a change in one does not automatically establish a change in the others.
When comparing papers, record the exact analog, cell system, medium, endpoint, reference material, and observation period. Distinguish a comparison made within one study from an apparent difference between unrelated studies using different methods.
Can an IGF-I assay measure LR3 automatically?
An assay’s analyte specificity matters. A 1998 study developed an ELISA that distinguished LR3IGF-I from native IGFs using antibody recognition of the modified analog [2]. This is a useful example of why assay compatibility should be demonstrated rather than assumed from a related name.
Before selecting a measurement method, review its intended analyte, calibration material, cross-reactivity, matrix effects, recovery, precision, and validated range. A method intended for native IGF-I should not automatically be treated as validated for LR3. Conversely, a method recognizing LR3 does not by itself establish a functional biological response.
How should a comparison be planned?
- Define the question: specify whether the objective involves receptor signaling, binding-protein interactions, or a downstream cellular endpoint.
- Choose relevant controls: include vehicle and appropriate reference materials, with analog identity documented.
- Document the model: record the cell system and conditions that could affect interpretation.
- Match the measurement: use an assay supported for the material and matrix being studied.
- Separate observations from inference: avoid translating a cell-system result into a general human-performance or clinical claim.
This framework supports review of laboratory evidence; it is not an administration protocol. The cited studies do not establish performance of a current Not Labs lot.
Which documents matter for the research material?
Review the IGF-1 LR3 product listing alongside the relevant batch documents. Confirm the lot connection, intended identity, analytical methods, sample information, and reported results.
Identity and chromatographic purity answer different questions. Content is another separate measurement. None of these alone demonstrates receptor activity, assay performance, sterility, or endotoxin status.
Use How to Read a Peptide COA and Testing & Verification to evaluate what a report actually supports before selecting material for a defined research application.
Primary references
- Francis et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213–223.
- Gajanandana et al. (1998). Measurement of an analog of insulin-like growth factor-I in blood plasma using a novel enzyme-linked immunosorbent assay. Journal of Endocrinology, 156(3), 407–414.